Cantel Medical Reports 19% Sales Growth And EPS Of $0.27 vs. $0.23 For The First Quarter Ended October 31, 2013

LITTLE FALLS, N.J., Dec. 5, 2013 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) reported a 17% increase in net income to a record $11,185,000, or $0.27 per diluted share, on a 19% increase in sales to a record $118,272,000 for the first quarter ended October 31, 2013. This compares with net income of $9,576,000, or $0.23 per diluted share, on sales of $99,681,000 for the first quarter ended October 31, 2012.

Andrew Krakauer, Cantel's President and CEO stated, "We are pleased to have delivered record sales and earnings this quarter. We achieved good financial performance in all three major business segments – Endoscopy, Water Purification and Filtration, and Healthcare Disposables. All three business units have greatly benefitted from further investments in new product development, sales and marketing programs, and the integration of recent acquisitions. Most importantly, for the second consecutive quarter we had strong organic sales growth of 10%. Further, our total sales growth of 19% demonstrates the success of our acquisition program."

Krakauer added, "Our Medivators Endoscopy business achieved robust organic sales growth of 19% in the quarter. All product categories were strong, including equipment, disinfectant chemicals, procedural products, as well as service and spare parts. Our Mar Cor Water Purification and Filtration segment continued its excellent performance as it has for the past two years with sales growth of 20% this quarter. Higher sales in this segment were led by increased shipments of central and portable water purification equipment. Sales in our Crosstex Healthcare Disposables business grew by 32%, mostly driven by the successful integration of the SPS Medical sterility assurance acquisition completed in November 2012. These substantial revenue increases drove the significantly improved operating earnings. Our strong results validate the effectiveness of our increasing investments in sales and marketing and new product development, which will support continued growth in all our major segments. Further, we are also taking an aggressive approach in building our international sales, marketing and operations teams to grow this part of our business over the medium-term. Such investments will accelerate over the next several quarters. Cantel will continue to be dedicated to the growing global infection prevention and control marketplace through both organic growth strategies and our continued commitment to an active acquisition program."

The Company also reported that its balance sheet at October 31, 2013 included current assets of $151,293,000, including cash of $28,453,000, a current ratio of 2.5:1, gross debt of $82,000,000 and stockholders' equity of $330,434,000. Krakauer stated, "We continue to maintain a strong balance sheet and generate substantial cash flow and EBITDAS. When compared with the same quarter last year, our EBITDAS grew by 15% to $24,148,000. We were able to reduce our net debt position by over $7 million to $53,547,000, during the quarter."

Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives.  Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products, and specialty packaging for infectious and biological specimens. Additionally, we provide technical service for our products. 

The Company will hold a conference call to discuss the results for the first quarter ended October 31, 2013 on Thursday, December 5, 2013 at 11:00 AM Eastern time. To participate in the conference call, dial (877) 407-8033 approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available from Thursday, December 5, 2013 at 2:00 PM through midnight on February 5, 2014 by dialing (877) 660-6853 and using conference ID # 13573107.

The call will be simultaneously broadcast live over the Internet on vcall.com at http://www.investorcalendar.com/IC/CEPage.asp?ID=171967.  A replay of the webcast will be available on Vcall for 90 days and via the investor relations page of the Cantel web site.

For further information, visit the Cantel website at www.cantelmedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

 

CANTEL MEDICAL CORP. 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

(unaudited)















Three Months Ended




October 31,




2013


2012








Net sales


$   118,272


$     99,681








Cost of sales


66,773


55,954








Gross profit


51,499


43,727








Expenses:






  Selling


15,764


13,413


  General and administrative


15,164


12,048


  Research and development


2,259


2,294


Total operating expenses


33,187


27,755








Income before interest and income taxes


18,312


15,972








Interest expense  


657


646


Interest income


(13)


(13)








Income before income taxes


17,668


15,339








Income taxes


6,483


5,763








Net income 


$     11,185


$      9,576








Earnings per common share - diluted  


$        0.27


$        0.23








Dividends per common share 


$        0.05


$        0.04








Weighted average shares - diluted 


41,373


41,042


 






CANTEL MEDICAL CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(unaudited)













October 31,


July 31,



2013


2013

                    Assets





     Current assets


$     151,293


$     150,660

     Property and equipment, net


46,565


46,465

     Intangible assets, net


73,512


75,929

     Goodwill


211,429


211,618

     Other assets


3,019


2,999



$     485,818


$     487,671






            Liabilities and stockholders' equity




     Current portion of long-term debt


$      10,000


$      10,000

     Other current liabilities


49,988


49,151

     Long-term debt


72,000


85,000

     Other long-term liabilities 


23,396


22,388

     Stockholders' equity


330,434


321,132



$     485,818


$     487,671






 

SUPPLEMENTARY INFORMATION


















Reconciliation of Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based

Compensation Expense ("EBITDAS")









(unaudited)














The reconciliation of EBITDAS with net income for the three months ended October 31, 2013 and 2012,

respectively, is as follows (in thousands):




















Three Months Ended







October 31,







2013


2012























Net income


$    11,185


$      9,576














Income taxes


6,483


5,763





Interest expense  


657


646





Interest income


(13)


(13)





Depreciation


1,937


1,760





Amortization


2,626


2,267





Loss on disposal of fixed assets


125


41














EBITDA


23,000


20,040














Stock-based compensation expense


1,148


958














EBITDAS


$    24,148


$    20,998
































EBITDAS is a measure of the Company's performance that is not required by, or presented in accordance with,

Generally Accepted Accounting Principles ("GAAP"). EBITDAS is a non-GAAP financial measure defined by the

Company as income before interest, taxes, depreciation, amortization and stock-based compensation expense.

The Company believes EBITDAS is an important valuation measurement for management and investors given

the increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitions and depreciation of capital equipment, has on the Company's net income. In particular, acquisitions have historically resulted in significant increases in amortization of intangible assets that reduced the Company's net income. Additionally, the Company regards EBITDAS as a useful measure of operating performance and cash flow before the effect of interest expense and complements operating income, net income and other GAAP financial 

performance measures. Generally, a non-GAAP financial measure is a numerical measure of a Company's 

performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. 

This measure, however, should be considered in addition to, and not as a substitute or superior to, net income, cash flows, or other measures of financial performance prepared in accordance with GAAP.

 

SOURCE Cantel Medical Corp.



RELATED LINKS
http://www.cantelmedical.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.